Onasemnogene abeparvovec (Zolgensma, formerly AVXS-101), a gene replacement therapy comprising an AAV vector containing the survival motor neuron 1 (SMN1) gene, has also been developed for spinal muscular atrophy type I [25]. Here, SMN1 is linked to spinal muscular atrophy, type 1.